CTBO (Cantabio Pharmaceuticals) FCF Margin %: 0.00% (As of Dec. 2018)


What is Cantabio Pharmaceuticals FCF Margin %?

Cantabio Pharmaceuticals CTBO FCF Margin % is 0.00% as of Dec. 2018.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cantabio Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2018 was $-0.26 Mil. Cantabio Pharmaceuticals's Revenue for the three months ended in Dec. 2018 was $0.00 Mil. Therefore, Cantabio Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2018 was 0.00%.

As of today, Cantabio Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Cantabio Pharmaceuticals's FCF Margin % or its related term are showing as below:


CTBO's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Cantabio Pharmaceuticals FCF Margin % Related Terms

Cantabio Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals FCF Margin % Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CTBO vs TNTY, ETNI, NTRR: FCF Margin % Comparison

For the Biotechnology subindustry, Cantabio Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantabio Pharmaceuticals FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's FCF Margin % falls into.


Cantabio Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cantabio Pharmaceuticals's FCF Margin for the fiscal year that ended in Mar. 2018 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2018 )/Revenue (A: Mar. 2018 )
=-0.623/0
= %

Cantabio Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2018 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2018 )/Revenue (Q: Dec. 2018 )
=-0.258/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Cantabio Pharmaceuticals (CTBO) has a FCF Margin % of 0.00% as of Dec. 2018. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' FCF Margin % too high?
Cantabio Pharmaceuticals' current FCF Margin % is 0.00%.
How does Cantabio Pharmaceuticals' FCF Margin % compare to TNTY and ETNI?
Cantabio Pharmaceuticals' FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current FCF Margin % is 0.00% as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.